SHANGHAI, Oct. 15, 2020 /PRNewswire/ -- On September 24, 111, Inc. (NASDAQ: YI) (the
"Company" or "111") and Hainan Huluwa Pharmaceutical Group Co.,
Ltd. (SH: 605199) ("Huluwa Pharmaceutical") signed a strategic
partnership agreement in Shanghai.
Mrs. LIU Jingping, Chairperson of Huluwa Pharmaceutical, and Dr.
YU Gang, Co-founder and Executive Chairman of 111, attended the
signing ceremony. Under the partnership, 111 will become the
omni-channel drug commercialization partner of Huluwa
Pharmaceutical. Both parties agreed to collaborate on "Internet +
Pharmaceutical" initiatives through leveraging 111's integrated
smart supply chains system to optimize the market reach of Huluwa
Pharmaceutical's pediatric healthcare products. In addition, the
two companies will continue to support innovation through data and
AI to enhance digital marketing and other value-additive
capabilities.
In her keynote speech at the signing ceremony, Mrs. LIU Jingping
mentioned that Huluwa Pharmaceutical and 111 have a solid
foundation to collaborate with the goal to leverage 111's advanced
digital technologies and smart supply chain to jointly pursue
infinite possibilities of "Internet + pharmaceutical" to create
greater values for both companies and ultimately benefit more
patients.
Dr. YU Gang commented that as a pioneer and leader in the online
healthcare sector, the Company remains committed to providing
universal access to safe and trusted pediatric medication in
China. With 111's omni-channel
commercialization platform and industry leading network, this
strategic partnership will benefit millions of pediatric patients
by enabling Huluwa Pharmaceutical's high-quality pediatric products
to reach millions of children in need of medication.
About Huluwa Pharmaceutical Group Co., Ltd.
Huluwa Pharmaceutical is committed to the mission "Keeping
Chinese Children Healthy". Specializing in children's health, it is
a leading high-tech company in China that integrates R&D and production
and sales, as well as the leading company in field of pediatric
respiratory system domestically.
About 111, Inc.
111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading
digital healthcare platform committed to digitally connecting
patients with healthcare products and services in China. The Company provides consumers with
better access to pharmaceutical products and healthcare services
directly through its online retail pharmacy, 1 Drugstore, and
indirectly through its offline virtual pharmacy network. The
Company also offers online healthcare services through its internet
hospital, 1 Clinic, which provides consumers with cost-effective
and convenient online consultation, electronic prescription
service, and patient management service. In addition, the Company's
online wholesale pharmacy, 1 Drug Mall, serves as a one-stop shop
for pharmacies to source a vast selection of pharmaceutical
products. With the largest virtual pharmacy network in China, 111 enables offline pharmacies to
better serve their customers with cloud-based services. 111 also
provides an omni-channel drug commercialization platform to its
strategic partners, which includes services such as digital
marketing, patient education, data analytics, and pricing
monitoring.
For more information on 111, please visit:
http://ir.111.com.cn/.
For more information, please contact:
111, Inc.
Investor Relations
Email: ir@111.com.cn
111, Inc.
Media Relations
Email: press@111.com.cn
Phone: +86-021-2053 6666 (China)
GCM Strategic Communications
IR Counsel
Email: 111.ir@gcm.international
View original
content:http://www.prnewswire.com/news-releases/111-inc-teams-up-with-huluwa-pharmaceutical-to-explore-the-new-domain-of-internet--pharmaceutical-301153281.html
SOURCE 111, Inc.